Author(s): Ganesh G. Dhakad, Sangita P. Shirsat, Kaveri P. Tmabe, Neha R. Jaiswal

Email(s): ganeshdhakad552@gmail.com

DOI: 10.52711/2321-5836.2022.00006   

Address: Ganesh G. Dhakad, Sangita P. Shirsat, Kaveri P. Tmabe, Neha R. Jaiswal
Ahinsa Institute of Pharmacy, Dondaicha 425408.
*Corresponding Author

Published In:   Volume - 14,      Issue - 1,     Year - 2022


ABSTRACT:
Gene-based therapies for cancer in clinical trials include strategies that involve augmentation of immunotherapeutic and chemotherapeutic approaches. These strategies include ex vivo and in vivo cytokine gene transfer, drug sensitization with genes for prodrug delivery, and the use of drug-resistance genes for bone marrow protection from high-dose chemotherapy. Inactivation of oncogene expression and gene replacement for tumor suppressor genes are among the strategies for targeting the underlying genetic lesions in the cancer cell. A review of clinical trial results to date, primarily in patients with very advanced cancers refractory to conventional treatments, indicates that these treatments can mediate tumor regression with acceptably low toxicity. Vector development remains a critical area for future research. Important areas for future research include modifying viral vectors to reduce toxicity and immunogenicity, increasing the transduction efficiency of nonviral vectors, enhancing vector targeting and specificity, regulating gene expression, and identifying synergies between gene-based agents and other cancer therapeutics.


Cite this article:
Ganesh G. Dhakad, Sangita P. Shirsat, Kaveri P. Tmabe, Neha R. Jaiswal. Review on Gene Therapy on Cancer. Research Journal of Pharmacology and Pharmacodynamics.2022;14(1):37-2. doi: 10.52711/2321-5836.2022.00006

Cite(Electronic):
Ganesh G. Dhakad, Sangita P. Shirsat, Kaveri P. Tmabe, Neha R. Jaiswal. Review on Gene Therapy on Cancer. Research Journal of Pharmacology and Pharmacodynamics.2022;14(1):37-2. doi: 10.52711/2321-5836.2022.00006   Available on: https://rjppd.org/AbstractView.aspx?PID=2022-14-1-6


REFERENCE:
1.    Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, Fulton LL, Dooling DJ, Ding L, Mardis ER, Wilson RK, Ally A, Balasundaram M, Butterfield YS, Carlsen R, Carter C, Chu A, Chuah E, Chun HJ, Coope RJ, Dhalla N, Guin R, Hirst C, Hirst M, Holt RA, Lee D, Li HI, Mayo M, Moore RA, Mungall AJ: Comprehensive molecular portraits of human breast tumours. Nature. 2012, 490 (7418):
2.    Shirley S, Heller R, Heller L: Electroporation gene therapy. Gene Therapy of Cancer. Edited by: Lattime EC, Gerson SL. 2013, San Diego (CA): Elsevier, 93-106. 3
3.    Baranyi L, Slepushkin V, Dropulic B: Ex vivo gene therapy: utilization of genetic vectors for the generation of genetically modified cell products for therapy. Gene Therapy of Cancer. Edited by: Lattime EC, Gerson SL. 2013, San Diego (CA): Elsevier, 3-18. 3
4.    Yuan Z, Pastoriza J, Quinn T, Libutti S: Targeting tumor vasculature using adeno-associated virus page vector coding tumor necrosis factor-a. Gene Therapy of Cancer. Edited by: Lattime EC, Gerson SL. 2013, San Diego (CA): Elsevier, 19-33. 3
5.    Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ: Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem. 1995, 270 (32): 18997-19007. 10.1074/jbc.270.32.18997.
6.    Tagami T, Suzuki T, Matsunaga M, Nakamura K, Moriyoshi N, Ishida T, Kiwada H: Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery. Int J Pharm. 2012, 422 (1–2): 280-289.
7.    Yang W, Sun T, Cao J, Liu F: Survivin downregulation by siRNA/cationic liposome complex radiosensitises human hepatoma cells in vitro and in vivo. Int J Radiat Biol. 2010, 86 (6): 445-457. 10.3109/09553001003668006.
8.    Wagner E, Plank C, Zatloukal K, Cotten M, Birnstiel ML: Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. Proc Natl Acad Sci U S A. 1992, 89 (17): 7934-7938. 10.1073/pnas.89.17.7934.
9.    Soltani F, Sankian M, Hatefi A, Ramezani M: Development of a novel histone H1-based recombinant fusion peptide for targeted non-viral gene delivery. Int J Pharm. 2013, 441 (1–2): 307-315.
10.    Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gulla A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, Munshi NC, Anderson KC, Neri A, Tagliaferri P, Tassone P: Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 2012, 18 (22): 6260-6270. 10.1158/1078-0432.CCR-12-1708.
11.    Soliman M, Nasanit R, Abulateefeh SR, Allen S, Davies MC, Briggs SS, Seymour LW, Preece JA, Grabowska AM, Watson SA, Alexander C: Multicomponent synthetic polymers with viral-mimetic chemistry for nucleic acid delivery. Mol Pharm. 2012, 9 (1): 1-13. 10.1021/mp200108q.
12.    Nie Y, Schaffert D, Rodl W, Ogris M, Wagner E, Gunther M: Dual-targeted polyplexes: one step towards a synthetic virus for cancer gene therapy. J Control Release. 2011, 152 (1): 127-134. 10.1016/j.jconrel.2011.02.028.
13.    Hackett PB, Largaespada DA, Switzer KC, Cooper LJ: Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res. 2013, 161 (4): 265-283. 10.1016/j.trsl.2012.12.005.
14.    Kwon S, Min J: Genetically engineered Salmonella typhimurium for targeted cancer therapy. Gene Therapy of Cancer. Edited by: Lattime EC, Gerson SL. 2013, San Diego (CA): Elsevier, 443-452. 3
15.    Benoit MR, Mayer D, Barak Y, Chen IY, Hu W, Cheng Z, Wang SX, Spielman DM, Gambhir SS, Matin A: Visualizing implanted tumors in mice with magnetic resonance imaging using magnetotactic bacteria. Clin Cancer Res. 2009, 15 (16): 5170-5177. 10.1158/1078-0432.CCR-08-3206.
16.    Baban CK, Cronin M, O'Hanlon D, O'Sullivan GC, Tangney M: Bacteria as vectors for gene therapy of cancer. Bioeng Bugs. 2010, 1 (6): 385-394. 10.4161/bbug.1.6.13146.
17.    Thomas CE, Ehrhardt A, Kay MA: Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003, 4 (5): 346-358. 10.1038/nrg1066.
18.    Kuroda S, Kagawa S, Fujiwara T: Selectively replicating oncolytic adenoviruses combined with chemotherapy, radiotherapy, or molecular targeted therapy for treatment of human cancers. Gene Therapy of Cancer. Edited by: Lattime EC, Gerson SL. 2013, San Diego (CA): Elsevier, 171-183. 3
19.    Zhang Y, Mukhopadhyay T, Donehower LA, Georges RN, Roth JA. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 1993; 4:451-60.
20.    Georges RN, Mukhopadhyay T, Zhang Y, Yen N, Roth JA. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res 1993; 53:1743-6.
21.    Grim J, Deshane J, Loechel F, Conry R, Siegel G, Feng M, et al. Induction of apoptotic cell death in erbB-2 over-expressing tumor cells of diverse histologic subtypes mediated by intracellular localization of an antierbB-2 SFV [abstract]. Cancer Gene Ther 1994; 1:333-4.
22.    Kashani-Sabet M, Funato T, Florenes VA, Fodstad O, Scanlon KJ. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res 1994; 54:900-2.
23.    Scanlon K, Jiao L, Funato T, Wang W, Tone T. Ribozyme-mediated cleavages of c-fos mRNA reduce gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad SciUSA 1991; 88:10591-5.
24.    Feng M, Cabrera G, Deshane J, Scanlon KJ, Curiel DT. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 1995; 55:2024-8.
25.    Chang EH, Miller PS, Cushman C, Devadas K, Pirollo KF, Ts’o PO, et al. Antisense inhibition of ras p21 expression that is sensitive to a point mutation. Biochemistry 1991; 30:8283-6.
26.    Richardson JH, Marasco WA. Intracellular antibodies: development and therapeutic potential. Trends Biotechnol 1995; 13:306-10.
27.    Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53.
28.    Knudson AG, Upton AC. Tumor suppressor gene workshop. Cancer Res 1990; 50:6765.
29.    Liebermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 1995; 11:199-210


Recomonded Articles:

Author(s): Jeena S, Venkateswaramurthy N, Sambathkumar R

DOI: 10.5958/2321-5836.2020.00004.X         Access: Open Access Read More

Author(s): Namrata Dwivedi, Bhavna Dwivedi, Skand Mishra, Yogeshwer Shukla.

DOI: Not Available         Access: Open Access Read More

Author(s): Arya B, Krishnaveni K, Sambathkumar R

DOI: 10.5958/2321-5836.2020.00005.1         Access: Open Access Read More

Author(s): Ganesh G. Dhakad, Sangita P. Shirsat, Kaveri P. Tmabe, Neha R. Jaiswal

DOI: 10.52711/2321-5836.2022.00006         Access: Closed Access Read More


Recent Articles




Tags